Limits...
CC chemokine ligand 18 correlates with malignant progression of prostate cancer.

Chen G, Liang YX, Zhu JG, Fu X, Chen YF, Mo RJ, Zhou L, Fu H, Bi XC, He HC, Yang SB, Wu YD, Jiang FN, Zhong WD - Biomed Res Int (2014)

Bottom Line: However, its involvement in human prostate cancer has not been fully elucidated.The effects of PCa cell migration, invasion, and apoptosis were tested.CCL18 upregulation was correlated with high Gleason score (P = 0.034) of patients with PCa. rCCL18 stimulation in PCa cells promoted cell migration and invasion but decreased DU145 cells apoptosis rate.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.

ABSTRACT

Background and aim: CC chemokine ligand 18 (CCL18) promotes malignant behaviors of various human cancer types. However, its involvement in human prostate cancer has not been fully elucidated. The aim of this study was to investigate the role of CCL18 in PCa.

Methods: Expression of CCL18 at mRNA and protein levels was detected using real-time qRT-PCR and immunohistochemistry analysis. We analyzed the associations of CCL18 expression with clinical features of human PCa. The effects of PCa cell migration, invasion, and apoptosis were tested. The efficiency of CCL18 on prostate tumor growth was assessed in a subcutaneous xenograft model.

Results: CCL18 expression was upregulated (both P < 0.01) in PCa tissues compared with those in noncancerous prostate tissues. CCL18 upregulation was correlated with high Gleason score (P = 0.034) of patients with PCa. rCCL18 stimulation in PCa cells promoted cell migration and invasion but decreased DU145 cells apoptosis rate. Furthermore, subcutaneous homografts models showed the increased tumor growth and tumor vascularization with the CCL18 stimulation, and the expression of Ki67, PCNA, and CD31 in CCL18 stimulation mice was also significantly increased.

Conclusions: Our data offer the convincing evidence that the upregulation of CCL18 may be involved in the malignant progression of PCa.

Show MeSH

Related in: MedlinePlus

CCL18 treatment promotes tumor growth, expression pattern, and localization of Ki67, PCNA in RM-1 xenograft. Treat the mice with CCL18 for 4 weeks. (a) Tumor size. (b) The gain of weight. (g) Weight of each mouse was measured once a week (P = 0.04). (c) Tumor volumes were measured at 28th day and the results were used to plot the graphs (P = 0.032). In CCL18 treatment group, the expression levels of Ki67 ((d), P < 0.001) and PCNA ((e), P < 0.001) proteins were significantly higher than those in the control group. (f) CD31 staining and HE staining of control group. (g) CD31 staining and HE staining of CCL18 treatment group.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4150478&req=5

fig5: CCL18 treatment promotes tumor growth, expression pattern, and localization of Ki67, PCNA in RM-1 xenograft. Treat the mice with CCL18 for 4 weeks. (a) Tumor size. (b) The gain of weight. (g) Weight of each mouse was measured once a week (P = 0.04). (c) Tumor volumes were measured at 28th day and the results were used to plot the graphs (P = 0.032). In CCL18 treatment group, the expression levels of Ki67 ((d), P < 0.001) and PCNA ((e), P < 0.001) proteins were significantly higher than those in the control group. (f) CD31 staining and HE staining of control group. (g) CD31 staining and HE staining of CCL18 treatment group.

Mentions: In order to validate the in vitro findings, we conducted in vivo experiments to test whether CCL18 could act as a tumor promoter in RM-1 homografts of mouse model. As the results show in Figure 5, rCCL18 stimulation significantly promoted tumor weight (P = 0.041, Figure 5(b)) and volume (P = 0.032, Figure 5(c)), which was consistent with its tumor promotive role in vitro.


CC chemokine ligand 18 correlates with malignant progression of prostate cancer.

Chen G, Liang YX, Zhu JG, Fu X, Chen YF, Mo RJ, Zhou L, Fu H, Bi XC, He HC, Yang SB, Wu YD, Jiang FN, Zhong WD - Biomed Res Int (2014)

CCL18 treatment promotes tumor growth, expression pattern, and localization of Ki67, PCNA in RM-1 xenograft. Treat the mice with CCL18 for 4 weeks. (a) Tumor size. (b) The gain of weight. (g) Weight of each mouse was measured once a week (P = 0.04). (c) Tumor volumes were measured at 28th day and the results were used to plot the graphs (P = 0.032). In CCL18 treatment group, the expression levels of Ki67 ((d), P < 0.001) and PCNA ((e), P < 0.001) proteins were significantly higher than those in the control group. (f) CD31 staining and HE staining of control group. (g) CD31 staining and HE staining of CCL18 treatment group.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4150478&req=5

fig5: CCL18 treatment promotes tumor growth, expression pattern, and localization of Ki67, PCNA in RM-1 xenograft. Treat the mice with CCL18 for 4 weeks. (a) Tumor size. (b) The gain of weight. (g) Weight of each mouse was measured once a week (P = 0.04). (c) Tumor volumes were measured at 28th day and the results were used to plot the graphs (P = 0.032). In CCL18 treatment group, the expression levels of Ki67 ((d), P < 0.001) and PCNA ((e), P < 0.001) proteins were significantly higher than those in the control group. (f) CD31 staining and HE staining of control group. (g) CD31 staining and HE staining of CCL18 treatment group.
Mentions: In order to validate the in vitro findings, we conducted in vivo experiments to test whether CCL18 could act as a tumor promoter in RM-1 homografts of mouse model. As the results show in Figure 5, rCCL18 stimulation significantly promoted tumor weight (P = 0.041, Figure 5(b)) and volume (P = 0.032, Figure 5(c)), which was consistent with its tumor promotive role in vitro.

Bottom Line: However, its involvement in human prostate cancer has not been fully elucidated.The effects of PCa cell migration, invasion, and apoptosis were tested.CCL18 upregulation was correlated with high Gleason score (P = 0.034) of patients with PCa. rCCL18 stimulation in PCa cells promoted cell migration and invasion but decreased DU145 cells apoptosis rate.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.

ABSTRACT

Background and aim: CC chemokine ligand 18 (CCL18) promotes malignant behaviors of various human cancer types. However, its involvement in human prostate cancer has not been fully elucidated. The aim of this study was to investigate the role of CCL18 in PCa.

Methods: Expression of CCL18 at mRNA and protein levels was detected using real-time qRT-PCR and immunohistochemistry analysis. We analyzed the associations of CCL18 expression with clinical features of human PCa. The effects of PCa cell migration, invasion, and apoptosis were tested. The efficiency of CCL18 on prostate tumor growth was assessed in a subcutaneous xenograft model.

Results: CCL18 expression was upregulated (both P < 0.01) in PCa tissues compared with those in noncancerous prostate tissues. CCL18 upregulation was correlated with high Gleason score (P = 0.034) of patients with PCa. rCCL18 stimulation in PCa cells promoted cell migration and invasion but decreased DU145 cells apoptosis rate. Furthermore, subcutaneous homografts models showed the increased tumor growth and tumor vascularization with the CCL18 stimulation, and the expression of Ki67, PCNA, and CD31 in CCL18 stimulation mice was also significantly increased.

Conclusions: Our data offer the convincing evidence that the upregulation of CCL18 may be involved in the malignant progression of PCa.

Show MeSH
Related in: MedlinePlus